系统性药物敏感性检测揭示达沙替尼或mTOR抑制剂与紫杉醇对卵巢颗粒细胞瘤细胞的协同生长抑制
本研究在体外用系统性药物敏感性和耐药性检测平台,筛选3例原发和4例复发成人型颗粒细胞瘤(AGCT)对230种抗癌药物的反应,并行mRNA测序,与人类黄体颗粒细胞和骨髓单核细胞比较。AGCT细胞对达沙替尼敏感,达沙替尼或依维莫司联合紫杉醇协同抑制细胞活力,肿瘤无已知致癌突变。作者认为这些联合方案值得进一步临床研究。
要点
- AGCT细胞对Src家族酪氨酸激酶抑制剂达沙替尼显示选择性敏感。
- 达沙替尼或mTOR抑制剂依维莫司与紫杉醇联用协同抑制AGCT细胞活力。
- 转录组分析未发现已知致癌突变,药物敏感性可能由选择性靶点表达介导。
核心结论
- 系统性功能筛选揭示达沙替尼或mTOR抑制剂与紫杉醇联合对AGCT细胞有选择性协同抑制作用,值得在复发或侵袭性AGCT中进一步临床研究。
- 高通量药物筛选和分子谱分析可为罕见妇科肿瘤发现新治疗选择。
研究设计与样本
- 体外研究:采用系统性药物敏感性和耐药性检测平台,筛选3例原发和4例复发AGCT对230种抗癌化合物的反应。
- 结合mRNA测序进行转录组分析,并与人类黄体颗粒细胞和骨髓单核细胞比较。
主要发现
- 患者来源的AGCT细胞对Src家族酪氨酸激酶抑制剂达沙替尼显示选择性敏感。
- 达沙替尼或mTOR抑制剂依维莫司与紫杉醇联合产生协同抑制AGCT细胞活力的效应。
- 达沙替尼的关键激酶靶点和mTOR通路成员在mRNA和蛋白水平持续表达,提示AGCT细胞存在多激酶信号依赖。
- 肿瘤转录组分析未发现已知致癌突变,提示药物敏感性可能由选择性靶点表达介导。
临床怎么用
- 作者认为,紫杉烷类与达沙替尼或mTOR抑制剂的联合方案值得在复发或侵袭性AGCT中进一步临床研究。
- 作者认为,高通量药物筛选和分子谱分析可为发现新治疗选择提供有效方法。
局限性
- 原文结论指出这些联合方案需进一步临床研究(warrants further clinical investigations)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Resistance to standard chemotherapy poses a major clinical problem in the treatment of ovarian cancer patients. Adult-type granulosa cell tumor (AGCT) is a unique ovarian cancer subtype for which efficient treatment options are lacking in advanced disease. To this end, systematic drug response and transcriptomics profiling were performed to uncover new therapy options for AGCTs. METHODS: The responses of three primary and four recurrent AGCTs to 230 anticancer compounds were screened in vitro using a systematic drug sensitivity and resistance testing (DSRT) platform, coupled with mRNA sequencing. The responses of the AGCTs were compared with those of human granulosa luteal cells and bone marrow mononuclear cells. RESULTS: Patient-derived AGCT cells showed selective sensitivity to the Src family tyrosine kinase inhibitor dasatinib. A combination of either dasatinib or an mTOR-inhibitor everolimus with paclitaxel resulted in synergistic inhibition of AGCT cell viability. The key kinase targets of dasatinib and members of the mTOR pathway were constantly expressed at mRNA and protein levels, indicating multikinase signal addictions in the AGCT cells. Transcriptomic characterization of the tumors revealed no known oncogenic mutations, suggesting that the drug sensitivity of AGCTs was rather conveyed by selective target expression. CONCLUSIONS: We used a systematic functional approach to reveal novel treatment options for a unique gynecological cancer. The selective synergy found between taxanes and dasatinib or mTOR inhibitors warrants further clinical investigations of these combinations in relapsed or aggressive AGCTs and demonstrate that high-throughput drug screening and molecular profiling can provide an effective approach to uncover new therapy options.
引用
- Haltia UM, Andersson N, Yadav B, et al. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Gynecol Oncol. 2017. PMID: 28104295. doi:10.1016/j.ygyno.2016.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。